{"classes":[{"categories":[{"measurements":[{"comment":"Here, 'NA' signifies that median, lower and upper limit of 95% confidence interval could not be estimated due to less number of participants with event.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Overall survival was measured from the date of first dose to the date of the participant's death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed or refractory waldenstrom's macroglobulinemia received ibrutinib 420 milligrams (mg) (3\\*140 mg capsules) orally once daily from Day 1 of Week 1 until disease progression, unacceptable toxicity, whichever occurs first.","id":"OG000","title":"Ibrutinib 420 mg"}],"paramType":"MEDIAN","populationDescription":"All treated analysis set included all enrolled participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From day of first dose (Day 1) until death due to any cause (up to 49.3 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}